Clinical Trial Update: A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China

View source ↗

Summary

A real-world study of IBI351 for KRAS G12C-positive non-small cell lung cancer in China, with the trial status listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI351

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Lung Cancer (NSCLC) | Status: NOT_YET_RECRUITING